Asahi Intecc (7747) investor relations material

Executive summary

• Net sales for the nine months ended March 31, 2026, rose 18.0% year-over-year to ¥108,366 million, driven by strong demand in both Medical and Device Divisions.

• Operating profit surged 45.5% year-over-year to ¥37,414 million, supported by sales growth and improved gross margin.

• Net income attributable to parent company shareholders increased 204.2% year-over-year to ¥26,657 million, aided by higher extraordinary gains and reduced impairment losses.

• Comprehensive income reached ¥32,866 million, up 490.8% year-over-year.

Financial highlights

• Gross profit increased 23.3% year-over-year to ¥76,788 million, with gross margin improving from 67.8% to 70.9%.

• EPS rose from ¥32.26 to ¥100.13, a 210.4% year-over-year increase.

• SGA expenses rose 7.7% year-over-year, mainly due to higher sales, R&D, and personnel costs.

• Ordinary profit rose 45.4% year-over-year to ¥37,207 million, aided by reduced subsidy income and lower foreign exchange losses.

• Total assets as of March 31, 2026, were ¥203,730 million, up ¥10,542 million from June 30, 2025.

Outlook and guidance

• Full-year forecast for fiscal year ending June 30, 2026: net sales ¥141,142 million (+17.6% YoY), operating profit ¥42,220 million (+40.4%), ordinary profit ¥42,688 million (+44.4%), profit attributable to owners of parent ¥30,556 million (+139.9%), and EPS ¥114.88.

• No changes to the previously announced upwardly revised forecast; actual results may differ due to market and economic uncertainties.